Bernard Scatton

Bernard Scatton's AcademicInfluence.com Rankings

Bernard Scatton

Philosophy

#5075

World Rank

#7794

Historical Rank

Logic

#2414

World Rank

#3402

Historical Rank

philosophy Degrees

Bernard Scatton

Biology

#6770

World Rank

#9560

Historical Rank

Neuroscience

#827

World Rank

#862

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Bernard Scatton's Degrees

PhD Neuroscience Université Paris Cité
Doctorate Medicine Université Paris Cité

Why Is Bernard Scatton Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Bernard Scatton's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease (1983) (719)
Nitric oxide mediates neuronal death after focal cerebral ischemia in the mouse. (1991) (508)
Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders (2002) (452)
Differential effects of inescapable footshocks and of stimuli previously paired with inescapable footshocks on dopamine turnover in cortical and limbic areas of the rat. (1982) (428)
Dopaminergic A10 neurones are involved in cognitive functions (1980) (371)
Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. (1997) (369)
Origin of dopaminergic innervation of the rat hippocampal formation (1980) (325)
Autoradiographic localization of D1 dopamine receptors in the rat brain with [3H]SCH 23390 (1986) (309)
Rimonabant reduces obesity‐associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats (2007) (302)
Autoradiographic distribution of the D1 agonist [3H]SKF 38393, in the rat brain and spinal cord. Comparison with the distribution of D2 dopamine receptors (1986) (275)
SSR180711, a Novel Selective α7 Nicotinic Receptor Partial Agonist: (II) Efficacy in Experimental Models Predictive of Activity Against Cognitive Symptoms of Schizophrenia (2007) (248)
Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents (2005) (247)
Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. I. Evidence for efficacy in models of focal cerebral ischemia. (1988) (237)
4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related (2002) (235)
Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. (1997) (234)
Dopaminergic and cholinergic lesions in progressive supranuclear palsy (1985) (232)
[3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. (1984) (227)
Differential regional development of tolerance to increase in dopamine turnover upon repeated neuroleptic administration. (1977) (212)
Neurochemical, Electrophysiological and Pharmacological Profiles of the Selective Inhibitor of the Glycine Transporter-1 SSR504734, a Potential New Type of Antipsychotic (2005) (210)
Presynaptic alpha-2 adrenoceptors play a major role in the effects of idazoxan on cortical noradrenaline release (as measured by in vivo dialysis) in the rat. (1987) (209)
Antidopaminergic properties of yohimbine. (1980) (208)
Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. (2002) (203)
Measurement of Endogenous Noradrenaline Release in the Rat Cerebral Cortex In Vivo by Transcortical Dialysis: Effects of Drugs Affecting Noradrenergic Transmission (1986) (200)
Central serotonergic nerves project to the pial vessels of the brain (1983) (192)
Differential Control by N‐Methyl‐D‐Aspartate and Kainate of Striatal Dopamine Release In Vivo: A Trans‐Striatal Dialysis Study (1988) (187)
Peripheral type benzodiazepine binding sites are a sensitive indirect index of neuronal damage (1987) (187)
Dopamine deficiency in the cerebral cortex in Parkinson disease (1982) (186)
SSR180711, a Novel Selective α7 Nicotinic Receptor Partial Agonist: (1) Binding and Functional Profile (2007) (176)
Evidence for, and nature of, the tonic inhibitory influence of habenulointerpeduncular pathways upon cerebral dopaminergic transmission in the rat (1986) (170)
N-methyl-D-aspartate-type receptors mediate striatal 3H-acetylcholine release evoked by excitatory amino acids (1982) (170)
Pharmacological studies on stress-induced increase in frontal cortical dopamine metabolism in the rat. (1986) (166)
Ifenprodil and SL 82.0715 as cerebral antiischemic agents. III. Evidence for antagonistic effects at the polyamine modulatory site within the N-methyl-D-aspartate receptor complex. (1990) (165)
Parkinson's disease and dementia (1987) (163)
The Cannabinoid CB1 Receptor Antagonist Rimonabant (SR141716) Inhibits Cell Proliferation and Increases Markers of Adipocyte Maturation in Cultured Mouse 3T3 F442A Preadipocytes (2006) (163)
Characterization of the excitatory amino acid receptor-mediated release of [3H]acetylcholine from rat striatal slices (1982) (160)
The NMDA receptor complex (1993) (156)
Ifenprodil and SL 82.0715 are antagonists at the polyamine site of the N-methyl-D-aspartate (NMDA) receptor. (1989) (151)
The pharmacotherapy of focal cortical ischaemia in the mouse (1990) (150)
Modulation of the gamma-aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin. (1995) (148)
Further evidence for the involvement of D2, but not D1 dopamine receptors in dopaminergic control of striatal cholinergic transmission. (1982) (144)
Stressful environmental stimuli increase extracellular DOPAC levels in the prefrontal cortex of hypoemotional (Roman high-avoidance) but not hyperemotional (Roman low-avoidance) rats. An in vivo voltammetric study (1988) (144)
Cortical modulation of striatal function (1982) (140)
Increased synthesis and release of dopamine in the striatum of the rat after amantadine treatment. (1970) (137)
Autoradiographic Localization of [3H]Zolpidem Binding Sites in the Rat CNS: Comparison with the Distribution of [3H]Flunitrazepam Binding Sites (1987) (133)
Amisulpride: from animal pharmacology to therapeutic action (1997) (132)
Differential responsiveness of the rat dorsal and median raphe 5‐HT systems to 5‐HT1 receptor agonists and p‐chloroamphetamine (1990) (131)
The potential use of GABA agonists in psychiatric disorders: Evidence from studies with progabide in animal models and clinical trials (1983) (130)
Effect of local injection of 8-OH-DPAT into the dorsal or median raphe nuclei on extracellular levels of serotonin in serotonergic projection areas in the rat brain (1992) (129)
Different plasticity changes in D1 and D2 receptors in rat striatal subregions following impairment of dopaminergic transmission (1988) (125)
Imaging of human brain lesions with an ω3 site radioligand (1988) (123)
SSR180575 (7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide), a peripheral benzodiazepine receptor ligand, promotes neuronal survival and repair. (2002) (120)
Evidence for a GABAergic inhibitory influence on serotonergic neurons originating from the dorsal raphe (1983) (119)
PET study of carbon-11-PK 11195 binding to peripheral type benzodiazepine sites in glioblastoma: a case report. (1991) (119)
Imaging of primary and remote ischaemic and excitotoxic brain lesions. An autoradiographic study of peripheral type benzodiazepine binding sites in the rat and cat (1988) (118)
Biochemical evidence for a transmitter role of dopamine in the rat hippocamus (1979) (116)
Distribution of central omega 1 (benzodiazepine1) and omega 2 (benzodiazepine2) receptor subtypes in the monkey and human brain. An autoradiographic study with [3H]flunitrazepam and the omega 1 selective ligand [3H]zolpidem. (1988) (114)
Progressive supranuclear palsy: anatomoclinical and biochemical considerations. (1987) (113)
Inhibitory influence of GABA on central serotonergic transmission. Raphe´nuclei as the neuroanatomical site of the GABAergic inhibition of cerebral serotonergic neurons (1985) (113)
Inhibitory influence of GABA on central serotonergic transmission. Involvement of the habenulo-raphe´pathways in the GABAergic inhibition of ascending cerebral serotonergic neurons (1985) (109)
Effect of dopamine agonists and neuroleptic agents on striatal acetylcholine transmission in the rat: evidence against dopamine receptor multiplicity. (1982) (108)
SSR591813, a Novel Selective and Partial α4β2 Nicotinic Receptor Agonist with Potential as an Aid to Smoking Cessation (2003) (105)
The gabaergic hypothesis of depression (1989) (104)
Denervation supersensitivity of striatal D2 dopamine receptors is restricted to the ventro- and dorsolateral regions of the striatum (1987) (103)
SL65.0155, A Novel 5-Hydroxytryptamine4 Receptor Partial Agonist with Potent Cognition-Enhancing Properties (2002) (99)
In vivo interaction of zolpidem with central benzodiazepine (BZD) binding sites (as labeled by [3H]Ro 15-1788) in the mouse brain. Preferential affinity of zolpidem for the omega 1 (BZD1) subtype. (1988) (99)
Determination of 5-hydroxytryptophan, serotonin and 5-hydroxyindoleacetic acid in rat and human brain and biological fluids by reversed-phase high-performance liquid chromatography with electrochemical detection. (1981) (97)
Dopamine metabolism in the mesolimbic and mesocortical dopaminergic systems after single or repeated administrations of neuroleptics (1976) (97)
Comparative autoradiographic distribution of central ω (benzodiazepine) modulatory site subtypes with high, intermediate and low affinity for zolpidem and alpidem (1993) (95)
gamma-Aminobutyric acid (GABA) receptor stimulation. III. Effect of progabide (SL 76002) on norepinephrine, dopamine and 5-hydroxytryptamine turnover in rat brain areas. (1982) (93)
Selective Release of Spermine and Spermidine from the Rat Striatum by N‐Methyl‐d‐Aspartate Receptor Activation In Vivo (1992) (91)
The quantification of brain lesions with anω 3 site ligand: a critical analysis of animal models of cerebral ischaemia and neurodegeneration (1990) (91)
Tail-pinch stress increases extracellular DOPAC levels (as measured by in vivo voltammetry) in the rat nucleus accumbens but not frontal cortex: antagonism by diazepam and zolpidem (1987) (89)
Degeneration of noradrenergic and serotonergic but not dopaminergic neurones in the lumbar spinal cord of parkinsonian patients (1986) (88)
Stimulation of the β3-Adrenoceptor as a Novel Treatment Strategy for Anxiety and Depressive Disorders (2008) (88)
Prevention by eliprodil (SL 82.0715) of traumatic brain damage in the rat. Existence of a large (18h) therapeutic window (1993) (87)
Urethane inhibits cardiovascular responses mediated by the stimulation of alpha-2 adrenoceptors in the rat. (1982) (86)
Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia (2008) (85)
gamma-Aminobutyric acid (GABA) receptor stimulation. II. Specificity of progabide (SL 76002) and SL 75102 for the GABA receptor. (1982) (84)
Distribution of monoaminergic, cholinergic, and GABAergic markers in the human cerebral cortex (1989) (81)
Increase inω3 (peripheral type benzodiazepine) binding sites in the rat cortex and striatum after local injection of interleukin-1, tumour necrosis factor-α and lipopolysaccharide (1991) (80)
Opposing effects of D-1 and D-2 receptor antagonists on acetylcholine levels in the rat striatum. (1986) (80)
Quantitative motor assessment in FALS mice: a longitudinal study (1997) (79)
SL651498: An Anxioselective Compound with Functional Selectivity for α2- and α3-Containing γ-Aminobutyric AcidA (GABAA) Receptors (2001) (79)
4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterization. (2002) (79)
Different neuronal location of [3H]SCH 23390 binding sites in pars reticulata and pars compacta of the substantia nigra in the rat (1986) (77)
Regional effects of neuroleptics on dopamine metabolism and dopamine-sensitive adenylate cyclase activity. (1977) (77)
gamma-Aminobutyric acid (GABA) receptor stimulation. IV. Effect of progabide (SL 76002) and other GABAergic agents on acetylcholine turnover in rat brain areas. (1982) (76)
Neuroprotective efficacy of N omega-nitro-L-arginine after focal cerebral ischemia in the mouse and inhibition of cortical nitric oxide synthase. (1994) (76)
SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms. (2003) (74)
Autoradiographic localization of D1 dopamine receptors in the rat brain with [3H]SKF 38393. (1985) (71)
Quantitative autoradiography of 3H-nomifensine binding sites in rat brain. (1985) (71)
Heterogeneous distribution of dopamine D2 receptors within the rat striatum as revealed by autoradiography of [3 H]N-n-propylnorapomorphine binding sites (1985) (67)
Increase in dopamine and DOPAC levels in noradrenergic terminals after electrical stimulation of the ascending noradrenergic pathways (1984) (66)
Biochemical and histological alterations induced by fluid percussion brain injury in the rat (1993) (65)
Antagonist properties of eliprodil and other NMDA receptor antagonists at rat NR1A/NR2A and NR1A/NR2B receptors expressed in Xenopus oocytes (1997) (65)
Autoradiographic localization and quantification of dopamine D2 receptors in normal human brain with [3H]N-n-propylnorapomorphine (1986) (64)
Neurotransmitter interactions in the basal ganglia (1987) (64)
Involvement of mesocorticolimbic dopaminergic systems in emotional states. (1990) (62)
Indoleaminergic mechanisms in brain vessels; localization, concentration, uptake and in vitro responses of 5-hydroxytryptamine. (1984) (61)
Substituted tetrahydro-beta-carbolines are possible candidates as endogenous ligand of the [3H]imipramine recognition site. (1984) (60)
N-Methyl-D-Aspartate Receptor Antagonists: A Novel Therapeutic Perspective for the Treatment of Ischemic Brain Injury (1991) (60)
Effect of the putative 5-HT1A receptor antagonist NAN-190 on rat brain serotonergic transmission. (1991) (59)
CB1 receptor‐mediated control of the release of endocannabinoids (as assessed by microdialysis coupled with LC/MS) in the rat hypothalamus (2007) (58)
The formation of deaminated metabolites of dopamine in the locus coeruleus depends upon noradrenergic neuronal activity (1985) (58)
[3H]RX 781094: A new antagonist ligand labels α2-adrenoceptors in the rat brain cortex (1983) (57)
Effects of the β3-adrenoceptor (Adrb3) agonist SR58611A (amibegron) on serotonergic and noradrenergic transmission in the rodent: Relevance to its antidepressant/anxiolytic-like profile (2008) (57)
Mesocorticolimbic dopaminergic systems and emotional states (1990) (57)
Neurochemical studies on the existence, origin and characteristics of the serotonergic innervation of small pial vessels (1985) (56)
EFFECTS OF CLONIDINE, PRAZOSIN AND PHENTOLAMINE ON HEART RATE AND CORONARY SINUS CATECHOLAMINE CONCENTRATION DURING CARDIOACCELERATOR NERVE STIMULATION IN SPINAL DOGS (1979) (55)
Brain 3,4-dihydroxyphenylethyleneglycol levels are dependent on central noradrenergic neuron activity. (1982) (55)
Antagonist properties of the stereoisomers of ifenprodil at NR1A/NR2A and NR1A/NR2B subtypes of the NMDA receptor expressed in Xenopus oocytes. (1996) (55)
5-HT1A receptor agonists inhibit carbachol-induced stimulation of phosphoinositide turnover in the rat hippocampus. (1988) (54)
Autoradiographic localization of muscarinic cholinergic receptors at various segmental levels of the human spinal cord (1984) (53)
Differential Effects of Forced Locomotion, Tail‐Pinch, Immobilization, and Methyl‐β‐Carboline Carboxylate on Extracellular 3,4‐Dihydroxyphenylacetic Acid Levels in the Rat Striatum, Nucleus Accumbens, and Prefrontal Cortex: An In Vivo Voltammetric Study (1990) (53)
Regulation of noradrenergic neuronal activity in the rat locus coeruleus by serotoninergic afferents (1985) (52)
SSR181507, A Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist. II: Behavioral Profile Predictive of an Atypical Antipsychotic Activity (2003) (52)
SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit (2005) (52)
Decrease in [3H]cocaine binding to the dopamine transporter in Parkinson's disease. (1983) (52)
SSR181507, A Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist. I: Neurochemical and Electrophysiological Profile (2003) (51)
Comparative in vivo and in vitro regional selectivity of central omega (benzodiazepine) site ligands in inhibiting [3H]flumazenil binding in the rat central nervous system. (1992) (51)
SSR126768A (4-Chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2- oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, Hydrochloride): A New Selective and Orally Active Oxytocin Receptor Antagonist for the Prevention of Preterm Labor (2004) (51)
Evidence for the involvement of presynaptic alpha-2 adrenoceptors in the regulation of norepinephrine metabolism in the rat brain. (1987) (50)
Effect of single and repeated administration of haloperidol and sulpiride on striatal and retinal dopamine turnover in the rat (1977) (50)
SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation. (2003) (50)
Lack of involvement of α2-adrenoceptors in the regulation of striatal dopaminergic transmission (1983) (50)
Excitatory amino acid receptor antagonists: a novel treatment for ischemic cerebrovascular diseases. (1994) (50)
Neuroprotective effects of eliprodil in retinal excitotoxicity and ischemia. (1999) (49)
Effect of clonidine on utilization and potassium-evoked release of adrenaline in rat brain areas (1979) (49)
Antagonism by N g-nitro-l-arginine ofl-glutamate-induced neurotoxicity in cultured neonatal rat cortical neurons. Prolonged application enhances neuroprotective efficacy (1993) (48)
Central benzodiazepine receptor occupancy by zolpidem in the human brain as assessed by positron emission tomography. (1996) (48)
Cerebral circulatory and metabolic effects of perivascular neurotransmitters. (1987) (48)
Modulation by GABA of cholinergic transmission in the striatum (1980) (46)
The effects ofN-methyl-d-aspartate and kainate lesions of the rat striatum on striatal ornithine decar☐ylase activity and polyamine levels (1991) (46)
Inhibitory GABAergic influence on striatal serotonergic transmission exerted in the dorsal raphe as revealed by in vivo voltammetry (1984) (46)
Influence of ascending serotonergic pathways on glucose use in the conscious rat brain. II. Effects of electrical stimulation of the rostral raphé nuclei (1988) (46)
Pharmacological characterization of serotonin-stimulated phosphoinositide turnover in brain regions of the immature rat. (1988) (45)
SL 82.0715, an NMDA antagonist acting at the polyamine site, does not induce neurotoxic effects on rat cortical neurons (1992) (45)
Sodium dependent [3H]cocaine binding associated with dopamine uptake sites in the rat striatum and human putamen decrease after dopaminergic denervation and in Parkinsons disease (1985) (43)
Pharmacological and molecular targets in the search for novel antipsychotics (2000) (42)
Increase in ω3 (Peripheral-Type Benzodiazepine) binding site densities in different types of human brain tumours (1992) (42)
Influence of lithium on biochemical manifestations of striatal dopamine target cell supersensitivity induced by prolonged haloperidol treatment. (1983) (41)
Imaging of human brain lesions with an omega 3 site radioligand. (1988) (41)
Pharmacological characterisation and autoradiographic distribution of polyamine-sensitive [3H]ifenprodil binding sites in the rat brain (1991) (41)
Cellular distribution of ω 3 (peripheral type benzodiazepine) binding sites in the normal and ischaemic rat brain: An autoradiographic study with the photoaffinity ligand [3H]PK 14105 (1990) (40)
SL651498: an anxioselective compound with functional selectivity for alpha2- and alpha3-containing gamma-aminobutyric acid(A) (GABA(A)) receptors. (2001) (40)
Differential modulation of [3H]TCP binding to the NMDA receptor by L-glutamate and glycine. (1988) (39)
NMDA antagonists block restraint-induced increase in extracellular DOPAC in rat nucleus accumbens. (1989) (38)
Omega 3 (peripheral type benzodiazepine binding) site distribution in the rat immune system: an autoradiographic study with the photoaffinity ligand [3H]PK 14105. (1989) (37)
Concentrations of Putative Neurovascular Transmitters in Major Cerebral Arteries and Small Pial Vessels of Various Species (1987) (37)
Cerebrospinal fluid amino acid and monoamine metabolite levels ofPapio papio: correlation witphotosensitivity (1986) (36)
The preclinical pharmacologic profile of tiapride (2001) (36)
SL 81.0385: A novel selective and potent serotonin uptake inhibitor (1988) (36)
Discovery of the mesocortical dopaminergic system: some pharmacological and functional characteristics. (1977) (35)
Neuroprotection afforded by a combination of eliprodil and a thrombolytic agent, rt-PA, in a rat thromboembolic stroke model (1997) (35)
Neuroanatomical site of the inhibitory influence of anxiolytic drugs on central serotonergic transmission (1986) (35)
Definitive disruption of spatial delayed alternation in rats after lesions in the ventral mesencephalic tegmentum (1979) (34)
Evidence for Differing Origins of the Serotonergic Innervation of Major Cerebral Arteries and Small Pial Vessels in the Rat (1991) (33)
Feeding or exposure to food odors increases extracellular DOPAC levels (as measured by in vivo voltammetry) in the prefrontal cortex of food-deprived rats (1989) (33)
Difluoromethyl ornithine protects against the neurotoxic effects of intrastriatally administered N-methyl-D-aspartate in vivo. (1991) (33)
Dihydropyridine- and omega-conotoxin-resistant, neomycin-sensitive calcium channels mediate the depolarization-induced increase in internal calcium levels in cortical slices from immature rat brain. (1992) (33)
[3H]imipramine binding in subcellular fractions of rat cerebral cortex after chemical lesion of serotonergic neurons. (1983) (32)
Zolpidem and alpidem: two imidazopyridines with selectivity for omega 1- and omega 3-receptor subtypes. (1990) (32)
Anorectic activities of serotonin uptake inhibitors: correlation with their potencies at inhibiting serotonin uptake in vivo and 3H-mazindol binding in vitro. (1988) (32)
Influence of ascending serotonergic pathways on glucose use in the conscious rat brain. I. Effects of electrolytic or neurotoxic lesions of the dorsal and/or median raphé nucleus (1988) (32)
The NMDA receptor antagonist eliprodil (SL 82.0715) blocks voltage-operated Ca2+ channels in rat cultured cortical neurons. (1994) (32)
Zolpidem functionally discriminates subtypes of native GABAA receptors in acutely dissociated rat striatal and cerebellar neurons (1996) (31)
In vivo and in vitro interaction of the novel selective histamine H1 receptor antagonist mizolastine with H1 receptors in the rodent. (1995) (30)
Fengabine, a novel antidepressant GABAergic agent. II. Effect on cerebral noradrenergic, serotonergic and GABAergic transmission in the rat. (1987) (30)
L-glutamate increases internal free calcium levels in synaptoneurosomes from immature rat brain via quisqualate receptors (1988) (30)
Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. (2008) (30)
Acute and chronic treatment with neuroleptics: similarities and differences in their action on nigrostriatal, mesolimbic, and mesocortical dopaminergic neurons. (1977) (30)
Preclinical profile of befloxatone, a new reversible MAO-A inhibitor. (1998) (30)
A radioenzymatic technique for the measurement of free and conjugated 3,4-dihydroxyphenylethyleneglycol in brain tissue and biological fluids (1982) (29)
Differential changes in DOPAC levels in the hippocampal formation, septum and striatum of the rat induced by acute and repeated neuroleptic treatment. (1981) (28)
Lack of neuroprotective effect of some σ ligands in a model of focal cerebral ischemia in the mouse (1992) (27)
Functional Bases for a Central Serotonergic Involvement in Classic Migraine: A Speculative View (1985) (27)
The GABA hypothesis of depression and antidepressant drug action. (1985) (26)
Amphetamine induced release of endogenous dopamine in vitro is not reduced following pretreatment with reserpine (1985) (25)
Trace amines inhibit the electrically evoked release of [3H]acetylcholine from slices of rat striatum in the presence of pargyline: similarities between beta-phenylethylamine and amphetamine. (1985) (25)
Platelet monoamine oxidase activity and plasma 3,4-dihydroxy-phenylethylene glycol levels during the menstrual cycle (1985) (25)
Effects of amisulpride, an atypical antipsychotic which blocks preferentially presynaptic dopamine autoreceptors, on integrated functional cerebral activity in the rat (1997) (25)
The Cannabinoid CB 1 Receptor Antagonist Rimonabant ( SR 141716 ) Inhibits Cell Proliferation and Increases Markers of Adipocyte Maturation in Cultured Mouse 3 T 3 F 442 A Preadipocytes (2006) (25)
Alterations of noradrenaline and serotonin uptake and metabolism in chronic cobalt-induced epilepsy in the rat (1983) (24)
GABA mimetics decrease extracellular concentrations of 5-HIAA (as measured by in vivo voltammetry) in the dorsal raphe of the rat (1985) (24)
Neurotoxic effects of the intrastriatal injection of spermine and spermidine: lack of involvement of NMDA receptors (1992) (24)
Acute and subacute effects of neuroleptics on dopamine synthesis and release in the rat striatum (2004) (23)
Effects of thioproperazine and apomorphine on dopamine synthesis in the mesocortical dopaminergic systems (1975) (22)
Anti-anaphylactic activity of the novel selective histamine H1 receptor antagonist mizolastine in the rodent. (1995) (22)
Pharmacological characterization of in vivo [3H]lfenprodil binding sites in the mouse brain. (1992) (22)
Differential Effects of Electrical Stimulation of the Dorsal Raphe Nucleus and of Cervical Sympathectomy on Serotonin and Noradrenaline Concentrations in Major Cerebral Arteries and Pial Vessels in the Rat (1990) (21)
Functional and biochemical evidence for the lack of cardiac presynaptic alpha-2 adrenoceptor stimulant properties of cirazoline (LD 3098), a potent alpha-1 adrenoceptor agonist in dogs and rats. (1982) (21)
The inhibitory GABAergic influence on striatal serotonergic neurons depends upon the habenulo-raphe pathways (1984) (20)
Relative selectivity of 6,7-dihydroxy-2-dimethylaminotetralin, N-n-propyl-3-(3-hydroxyphenyl)piperidine, N-n-propylnorapomorphine and pergolide as agonists at striatal dopamine autoreceptors and postsynaptic dopamine receptors. (1985) (20)
Tolerance to increases in striatal acetylcholine concentrations after repeated administration of apomorphine dipivaloyl ester (1979) (19)
Dopamine metabolism, spiperone binding and adenylate cyclase activity in the adult rat hippocampus after ingrowth of dopaminergic neurones from embryonic implants (1979) (19)
Ischemic stroke: treatment on the horizon. (1996) (19)
Interaction of GABA mimetics with nigro-striatal dopamine neurons (1979) (19)
Increase in omega 3 (peripheral type benzodiazepine) binding sites in the rat cortex and striatum after local injection of interleukin-1, tumour necrosis factor-alpha and lipopolysaccharide. (1991) (18)
Zolpidem, a novel nonbenzodiazepine hypnotic. II. Effects on cerebellar cyclic GMP levels and cerebral monoamines. (1986) (18)
Increase in striatal acetylcholine levels by GABA mimetic drugs: lack of involvement of the nigro-striatal dopaminergic neurons. (1979) (18)
Release of spermidine from the rat cortex following permanent middle cerebral artery occlusion (1995) (18)
Increase in striatal acetylcholine levels by GABAergic agents: dependence on corticostriatal neurons (1980) (18)
Peripheral Type Benzodiazepine Binding Sites as a Tool for the Detection and Quantification of CNS Injury (1999) (17)
Amphetamine-induced increase in rat cerebral blood flow: Apparent lack of catecholamine involvement (1978) (17)
Protracted treatment with diazepam reduces benzodiazepine1 receptor-mediated potentiation of gamma-aminobutyric acid-induced currents in dissociated rat hippocampal neurons. (1996) (17)
Monoamine abnormalities in the brain of scrapie-infected rats (1984) (17)
Evidence for the Existence of a Dopaminergic Innervation of the Rat and Human Hippocampal Formation (1982) (17)
Interactions between GABA, dopamine, acetylcholine, and glutamate-containing neurons in the extrapyramidal and limbic systems. (1981) (17)
Time course of the changes in striatal acetylcholine levels induced by pergolide and haloperidol after lesion of the nigrostriatal dopaminergic pathways in the rat (1984) (16)
Tolerance to stereotyped behaviour and to decrease in striatal homovanillic acid levels after repeated treatment with apomorphine dipivaloyl ester. (1977) (16)
Effect of repeated treatment with neuroleptics on dopamine metabolism in cell bodies and terminals of dopaminergic systems in the rat brain. (1980) (16)
Autoradiographic Visualization and Quantification of Dopamine Receptors and Uptake Sites in the Rat and Human CNS (1986) (16)
EFFECTS OF ANTIHYPERTENSIVES AND OTHER DRUGS ON CENTRAL ADRENALINE UTILISATION (1980) (15)
In vivo voltammetric measurement of extracellular 5-hydroxyindoleacetic acid in the denervated striatum after transplantation of mesencephalic raphe neurons (1984) (15)
Regional pattern of increased ω 3 (peripheral type benzodiazepine) binding site densities in the rat brain induced by systemic injection of kainic acid (1991) (15)
In vivo voltammetric measurement of extracellular DOPAC levels in the anteromedial prefrontal cortex of the rat (1986) (15)
Functional mapping of the effects of lesions of the habenular nuclei and their afferents in the rat (1986) (15)
Ornithine decarboxylase inhibition or NMDA receptor antagonism reduce cortical polyamine efflux associated with dialysis probe implantation (1993) (14)
Acute and subacute effects of haloperidol on dopac levels in the substantia nigra and ventral tegmental area of rat brain. (1979) (14)
Dopamine deficiency in Parkinson's disease (1984) (13)
Raised extracellular potassium relieves the blockade by magnesium of NMDA-induced cerebellar cyclic GMP production (1987) (13)
SL 85.0324: a novel benzimidazole derivative with selective histamine H1-receptor antagonist properties (1990) (12)
Block of P-type Ca2+ channels by the NMDA receptor antagonist eliprodil in acutely dissociated rat Purkinje cells. (1995) (12)
[A specific domain (the omega 1 site) of the GABA(A) receptor may be implicated in the hypnotic effects of zolpidem]. (1990) (12)
New perspectives for the treatment of disorders of sleep and arousal. (2007) (12)
Subchronic administration of GABAergic agonists elevates [3H]GABA binding and produces tolerance in striatal dopamine catabolism (1985) (12)
Critical review on quantitative autoradiography of D1 and D2 dopaminergic receptors in the striatum of the mammalian brain: differential localization and plastic changes after pharmacological manipulation and dopaminergic input disruption. (1989) (12)
Ifenprodil and Eliprodil: Neuroprotective NMDA Receptor Antagonists and Calcium Channel Blockers (1997) (12)
SL25.1131 [3(S),3a(S)-3-Methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a New, Reversible, and Mixed Inhibitor of Monoamine Oxidase-A and Monoamine Oxidase-B: Biochemical and Behavioral Profile (2004) (11)
Lesion of nucleus basalis magnocellularis decreases [3H]hemicholinium-3 binding (as measured by autoradiography) in the amygdala and frontal cortex of the rat (1986) (11)
Further evidence for, and nature of, the facilitatory GABAergic influence on central noradrenergic transmission (1985) (11)
Decrease in both choline acetyltransferase activity and EEG patterns in the hippocampal formation of the rat following septal macroelectrode implantation (1984) (11)
Measurement of 5-HIAA levels in ventricular CSF (by LCEC) and in striatum (byin vivo voltammetry) during pharmacological modifications of serotonin metabolism in the rat (2005) (11)
Noradrenaline Antagonizes and Ouabain Potentiates the Effects of iV‐Methyl‐D‐Aspartate on Rat Cerebellar Cyclic GMP Production (1988) (11)
High doses of haloperidol in schizophrenia. A clinical, biochemical, and pharmacokinetic study. (1982) (11)
Evidence for a Central Serotonergic Projection to the Cerebral Resistance Vessels: Possible Functional Implications (1985) (11)
Gaba-Acetylcholine Interaction in the Rat Striatum (1981) (11)
GABA receptor agonists and extrapyramidal motor function: therapeutic implications for Parkinson's disease. (1987) (10)
Effect of eliprodil, an NMDA receptor antagonist acting at the polyamine modulatory site, on local cerebral glucose use in the rat brain (1994) (10)
Modulation of cholinergic transmission in the rat brain by GABA (1980) (10)
Drug-induced changes of epinephrine turnover in the rat hypothalamus. (1981) (10)
2-Oxo-[14C]glutarate is taken up by glutamatergic nerve terminals in the rat striatum (1986) (10)
Muscarinic Receptor‐Mediated Increase in Extracellular Inositol 1,4,5‐Trisphosphate Levels in the Rat Hippocampus: An In Vivo Microdialysis Study (1994) (10)
N-methyl-C-aspartate-type receptors mediate striatal 3H-acetylcholine release evoked by excitatory amino acids. (1982) (9)
Cortical ablation fails to influence striatal dopamine target cell supersensitivity induced by nigrostriatal denervation in the rat (1987) (9)
Dopamine receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database (2019) (9)
Anti-anaphylactic activity of the non sedative histamime H1 receptor antagonist SL 85.0324 in the rat and guinea pig (1990) (9)
Lesions of the posterior septum or of the habenula decrease [3H]hemicholinium-3 binding (as measured by autoradiography) in the interpeduncular nucleus of the rat (1987) (9)
Subunit composition of rat ventral spinal cord GABAA receptors, assessed by single cell RT‐multiplex PCR (2000) (9)
Quantitative Autoradiographic Localization of Dopamine Receptors and Uptake Sites in the Rat and Human CNS (1985) (9)
Recent findings in central dopaminergic and cholinergic neurotransmission of roman high- and low-avoidance (RHA/Verh and RLA/Verh) rats (1987) (8)
Pharmacological and therapeutic actions of GABA receptor agonists. (1983) (8)
Platelet monoamine oxidase activity and plasma 3,4-dihydroxyphenylethylene glycol levels during the menstrual cycle. (1985) (8)
Dopaminergic Neurons: Basic Aspects (1989) (8)
The psychopharmacology of GABA synapses: update 1989. (1990) (8)
Action of the palmitic ester of pipotiazine on dopamine metabolism in the nigro-striatal, meso-limbic and meso-cortical systems (2004) (8)
Effects of the GABA receptor agonist, progabide, upon local cerebral glucose utilization (1987) (8)
Differential influence of GABA-ergic agents on dopamine metabolism in extrapyramidal and limbic systems of the rat (1980) (7)
Proliferation of omega 3 binding sites in the immune organs and leg infiltrate of rats with adjuvant induced arthritis. (1990) (7)
Autoradiographic localization of dopamine receptors in the spinal cord of the rat using [3H]-N-propylnorapomorphine (2005) (7)
Decrease in plasma levels of 3,4-dihydroxyphenylethyleneglycol in major depression (2004) (7)
Implication of the polyamines in the neurotoxic effects of N-methyl-D-aspartate. (1992) (7)
Lack of involvement of alpha 2-adrenoceptors in the regulation of striatal dopaminergic transmission. (1983) (6)
Pharmacological, hemodynamic and biochemical mechanisms involved in the blood pressure lowering effects of pergolide, in normotensive and hypertensive dogs. (1985) (6)
Effect of the new gamma-aminobutyric acid agonist SL 76 002 on striatal acetylcholine: relation to neuroleptic-induced extrapyramidal alterations. (1980) (6)
SL651498: An Anxioselective Compound with Functional Selectivity for a 2 - and a 3 -Containing g -Aminobutyric Acid A (GABA A ) Receptors (2001) (6)
Lack of correlation between DST results and urinary MHPG in depressed inpatients (2005) (6)
Effects of cyclo (Leu-Gly) on neurochemical indices of striatal dopaminergic supersensitivity induced by prolonged haloperidol treatment. (1984) (6)
Operation of Presynaptic α2‐Adrenoceptors In Vivo in the Rat Brain (1990) (6)
The Use of in Vivo Voltammetry to Investigate Functional Recovery with Transplants and Neurotransmitter Interactions in the Rat Brain (1986) (5)
Effect of prolonged clonidine treatment and its withdrawal on noradrenaline turnover in the cerebral cortex and medulla oblongata of the spontaneously hypertensive rat (1987) (5)
SUBSENSITIVITY OF STRIATAL DOPAMINE TARGET CELLS AFTER REPEATED TREATMENT WITH APOMORPHINE DIPIVALOYL ESTER (1979) (5)
Comparative In vivo and In vitro Selectivity of Zolpidem for ω (Benzodiazepine) Modulatory Site Subtypes (1995) (5)
Influence of GABA mimetics and lithium on biochemical manifestations of striatal dopamine target cell hypersensitivity. (1985) (5)
Autoreceptor-mediated Control of Serotonin Release in the Rat Brain in vivo (1991) (5)
Lack of correlation between plasma DOPEG and urinary MOPEG levels in depressed patients (1986) (5)
The imidazopyridine derivatives zolpidem and alpidem discriminate between central ω (benzodiazepine) receptor subtypes in rat brain sections (1991) (5)
Dementia in Patients with Parkinson’s Disease: Review of Biochemical Data (1985) (5)
Modulation of striatal serotonin metabolism by baclofen, a gamma-aminobutyric acidB receptor agonist. (1989) (4)
Prolonged application of NG-nitro-l-arginine prevents glutamate induced neurotoxicity in neonatal rat cortical neurons (1992) (4)
Subsensitivity of striatal and mesolimbic dopamine target cells after repeated treatment with apomorphine dipivaloyl ester (1978) (4)
S-19-1 Novel neuroleptics acting on presynaptic dopaminergic receptors (1995) (3)
Pharmacological properties and autoradiographic distribution of the binding of 3H-SL 85.0324, a non sedative H1 receptor antagonise, in the guinea pig brain (1990) (3)
5-HT1C receptors mediate phosphoinositide turnover activation in the immature rat hippocampus. (1992) (3)
Lack of circadian rhythm in plasma levels of 3,4-dihydroxyphenylethyleneglycol in healthy human subjects (2004) (3)
Plasma 3,4-dihydroxyphenylethyleneglycol and therapeutic response to maprotiline and indalpine in major depression. (1986) (3)
Chapter 3 – Measurement and Expression of Drug Effects (2008) (3)
Distribution of dopamine, noradrenaline and adrenaline in coronal sections of the rat lower brainstem (1985) (3)
GABA mimetics increase extracellular DOPAC (as measured by in vivo voltammetry) in the rat locus coeruleus (1986) (3)
Temporal effects of habenular lesions on glucose utilization in the anterior raphé nuclei of the rat (1986) (3)
[The place of amisulpride in the atypical neuroleptic class]. (1996) (3)
World Federation of Neurology Research Group on Cerebrovascular Disease: 15th Salzburg Conference on Cerebral Vascular Disease (1991) (3)
Plasma 3,4-dihydroxyphenylethyleneglycol levels in depressed patients with and without abnormal dexamethasone suppression. (1986) (3)
[Study of noradrenaline metabolism in depressed patients by the determination of plasma dihydroxyphenylethylene glycol]. (1983) (2)
DOPAMINE RECEPTORS MODULATING THE RELEASE OF SEVERAL NEUROTRANSMITTERS IN THE PERIPHERAL AND CENTRAL NERVOUS SYSTEM (1984) (2)
Lithium treatment increases norepinephrine turnover in the plasma of healthy subjects. (1993) (2)
Non-benzodiazepine anxiolytics: Potential activity of phenylpiperazines without 3H-diazepam displacing action (1985) (2)
Excitatory Amino Acid Influence on Striatal Cholinergic Transmission (1986) (2)
90-9 Autoradiographic distribution of [3H]-befloxatone, a selective and reversible MAO-A inhibitor in the rat brain (1997) (2)
The Pharmacological Properties of Tiapride (1998) (2)
Functional Similarities Between Benzamides and Other Neuroleptics (1983) (2)
Eliprodil: a novel neuroprotective agent acting at a modulatory site of the NMDA receptor (1994) (2)
Modulation by GABA of cholinergic transmission in rat brain (1979) (2)
GABAERGIC MECHANISMS AND ANTIDEPRESSANT THERAPY (1984) (2)
[3H]RX 781094: a new antagonist ligand labels alpha 2-adrenoceptors in the rat brain cortex. (1983) (2)
DOPAMINE NEURON ACTIVITY: EFFECT OF SL 76 002, A NEW GABA MIMETIC CANDIDATE (1979) (2)
Interaction of SL 85.0274, a novel anxioselective imidazopyridine, with ω1–2 (benzodiazepine) receptors in the rodent and primate brain (1990) (2)
Hypophysectomy fails to affect the supersensitivity of striatal dopamine target cells induced by prolonged haloperidol treatment. (1984) (2)
Functional expression and properties of NMDA receptor subtypes (1994) (1)
GABA Theory of Depression and Antidepressant Drug Action (1989) (1)
[Use of haloperidol in high doses in schizophrenia. Clinical, biochemical and pharmacokinetic study]. (1982) (1)
Antidepressant and potential antimanic actions of GABA receptor agonists (1983) (1)
Catecholamines II (1989) (1)
Effect of eliprodil, an NMDA receptor antagonist acting at the polyamine modulatory site, on local cerebral glucose use in the rat in the rat brain. (1994) (1)
INFLUENCE OF PSYCHOTROPIC AGENTS ON EPINEPHRINE TURNOVER IN THE RAT HYPOTHALAMUS (1984) (1)
Use of ifenprodil and diastereoisomers, for the manufacture of drugs which are useful in the treatment of peripheral neuropatiatilojen and degenerative diseases of the central nervous (1995) (1)
The potential of NMDA antagonists for stroke treatment (1991) (1)
The role of cytokines in neural pathology (1991) (1)
[Biochemical mechanism of action of neuroleptics (author's transl)]. (1981) (1)
THE NMDA MACROMOLECULAR COMPLEX AS A TARGET FOR THE DEVELOPMENT OF ANTI‐ISCHEMIC DRUGS. (1992) (1)
Progabide in Parkinson's disease (1987) (1)
Non-benzodiazepine anxiolytics: potential activity of phenylpiperazines without 3H-diazepam displacing action. (1984) (1)
Hypothesis of a deficiency of central noradrenergic input in DST nonsuppressor depressed patients. A clinical study with determination of DST and plasma DOPEG: negative results. (1985) (1)
Sodium dependence of NMDA's effects on cyclic GMP production in immature rat cerebellar slices (1988) (1)
LACK OF EVIDENCE FOR AXONAL TRANSPORT OF D1 AND D2 RECEPTORS IN THE NIGRO‐STRIATAL PATHWAY OF THE RAT (1988) (1)
65-67 Amisulpride is a preferential D3 dopamine receptor antagonist (1997) (1)
PHARMACOLOGY OF GABA RECEPTOR AGONISTS (1984) (1)
Dopamine metabolism in the rat retina and brain after acute and repeated treatment with neuroleptics. (1978) (1)
Langer et al. reply (1998) (1)
Proposal for an ‘omega modulatory site’ nomenclature to replace the benzodiazepine receptor denomination (1991) (1)
Place of Indalpine in Psychiatric Treatment (1984) (1)
Neuroprotective Effects of Eliprodil in a Rat Hippocampal Slice Hypoxia Model (1997) (0)
Research report Effec(of eliprodil, an NMDA receptor antagonist acting at the polyamine modulatory site, on local cerebral glucose use in the rat brain (1994) (0)
EFFECT OF NEUROLEPTICS ON DOPAMINE METABOLISM IN THE RAT FRONTAL CORTEX (1980) (0)
Pharmaceutical compositions containing nicotine and their application into tobacco weaning (1999) (0)
Subject Index Vol. 14, 1985 (1985) (0)
Pharmaceutical compositions based eliprodil and a thrombolytic agent and their application in therapeutic (1995) (0)
Modification of cerebral monoamines in the rat in the course of experimental scrapie (1984) (0)
Use of eliprodil and its enantiomers for the preparation of medicaments useful in preventing neuropathiesinduites by agentsanticancereux (1994) (0)
2064 – ACTION OF MUSCIMOL, SL 76 002 AND BACLOFEN ON THE TURNOVER OF DOPAMINE AND NORADRENALINE IN THE RAT BRAIN (1978) (0)
Contents, Vol. 14, 1985 (1985) (0)
Therapeutic potential of the atypical non-competitive NMDA receptor antagonists, ifenprodil and SL 82.0715, in ischaemic cerebrovascular diseases (1990) (0)
Psychopharmacology of Positive and Negative Symptoms of Schizophrenia: Behavioural Models and Pharmacological Profiles (1996) (0)
S-73-5 Antagonists of NMDA receptor modulatory sites: Therapeutic perspectives (1996) (0)
Distribution of monoaminergic cholinergic gabaergic and peptidergic markers in the human cerebral cortex (1987) (0)
BASAL GANGLIA MECHANISMS INVOLVED IN MOVEMENT DISORDERS (1992) (0)
P-5-3 Effect of a combination of befloxatone and a 5HT1A receptor antagonist on rat cortical serotonin release (1996) (0)
26-7 Which pharmacological properties are responsible for the clinical efficacy and good tolerability of Tiapride? (1997) (0)
GABA Receptors, Depression and Antidepressant Drug Action (1987) (0)
[Study of the metabolism of cerebral noradrenaline in depressed patients by the assay of plasma dihydroxyphenylethylene glycol]. (1985) (0)
Ifenprodil and SL 82.0715 antagonize the effects of NMDA via a polyamine-sensitive modulatory site (1990) (0)
Operation of presynaptic alpha 2-adrenoceptors in vivo in the rat brain. (1990) (0)
Pharmaceutical compositions containing nicotine and their use in smoking cessation (1999) (0)
[The discovery process in the pharmaceutical industry]. (2009) (0)
[Physiopathology and genetics of epilepsy: recent data]. (2011) (0)
S-51-4: Pharmacological profile of befloxatone, a reversible and selective MAO-A inhibitor (1996) (0)
An Obituary to Jacques Glowinski (1936-2020). (2021) (0)
NEUROPSYCHOPHARMACOLOGICAL PROFILE OF LITOXETINE, A NEW SELECTIVE INHIBITOR OF SEROTONIN UPTAKE (1992) (0)
Use of ifenprodil and its enantiomers for the preparation of medicaments useful in the treatment of peripheral neuropathies and neurodegenerative diseases central (1994) (0)
42-4 Preclinical profile of befloxatone, a reversible and selective MAO-A inhibitor (1997) (0)
Urinary 3-methoxy, 4-hydroxyphenylethylene glycol and therapeutic response to maprotiline and indalpine in major depression (2005) (0)
EFFECT OF CARDIAC PRESYNAPTIC α-ADRENOCEPTOR STIMULATION BY CLONIDINE AND ITS ANTAGONISM BY PHENTOLAMINE AND PRAZOSIN ON CORONARY SINUS PLASMA NOREPINEPHRINE OVERFLOW IN DOGS (1979) (0)
Interaction of GABA hihetics with nigro-striatal dopamine neurons (1979) (0)
POSTER ABSTRACTS (2001) (0)
S37 INVOLVEMENT OF THE ENDOCANNABINOID SYSTEM IN THE REGULATION OF FEEDING BEHAVIOUR AND BODY WEIGHT: PHARMACOLOGICAL EFFECTS OF RIMONABANT, A CB1 CANNABINOID RECEPTOR ANTAGONIST (2005) (0)
Target receptors for hypnotics: Relevance to pharmacological profile and therapeutic action (1993) (0)

This paper list is powered by the following services:

Bernard Scatton's Academic­Influence.com Rankings

Bernard Scatton's Degrees

Why Is Bernard Scatton Influential?

Bernard Scatton's Published Works

Published Works

Bernard Scatton's AcademicInfluence.com Rankings